Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer

Blok, E.J.; Kroep, J.R.; Kranenbarg, E.M.K.; Duijm-De Carpentier, M.; Putter, H.; Liefers, G.J.; ... ; TEAM Study Group (2018)

Article / Letter to editor

• Breast cancer
• Extended endocrine therapy
• Clinical trial
• Compliance
• Early treatment discontinuation
• Adverse events
• Survival
• Aromatase inhibitor
• Tamoxifen

• All authors: Blok, E.J.; Kroep, J.R.; Kranenbarg, E.M.K.; Duijm-De Carpentier, M.; Putter, H.; Liefers, G.J.; Nortier, J.W.R.; Rutgers, E.J.T.; Seynaeve, C.M.; Velde, C.J.H. van de; IDEAL Study Group; TEAM Study Group
• Date: 2018-05-31
• Journal: European Journal of Cancer
• Volume: 95
• Pages: 59 - 67
• DOI: doi:10.1016/j.ejca.2018.03.014